Tai‐Shuan Lai, Mei‐Hsuan Lee, Hwai‐I Yang, San‐Lin You, Sheng‐Nan Lu, Li‐Yu Wang, Yong Yuan, Gilbert L'Italien, Kuo‐Liong Chien, Chien‐Jen Chen, for the REVEAL‐HCV Study Group – 2 April 2017 – The association between hepatitis C virus (HCV) infection and end‐stage renal disease (ESRD) remains controversial without considering the role of HCV viral load and genotype. This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESRD.

Ming‐Ling Chang, Yun‐Fan Liaw – 2 April 2017

Heng Fan, Jian‐hua Zhu – 2 April 2017

Ewan Forrest – 1 April 2017

Chengyou Jia, Vivian Medina, Chenchang Liu, Lina He, Daohai Qian, Taojian Tu, Curtis T. Okamoto, Bangyan L. Stiles – 1 April 2017 – Liver kinase B 1 (LKB1 or STK11) and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) are two tumor suppressors that regulate the mammalian target of rapamycin signaling pathway. Deletion studies show that loss of either Lkb1 (Lkb+/–) or Pten (PtenloxP/loxP; Alb‐Cre+) leads to liver injury and development of hepatocarcinoma. In this study, we investigated the crosstalk of LKB1 and PTEN loss during tumorigenesis and liver development.

Bing‐liang Lin, Jun‐feng Chen, Wei‐hong Qiu, Ke‐wei Wang, Dong‐ying Xie, Xiao‐yong Chen, Qiu‐li Liu, Liang Peng, Jian‐guo Li, Yong‐yu Mei, Wei‐zhen Weng, Yan‐wen Peng, Hui‐juan Cao, Jun‐qiang Xie, Shi‐bin Xie, Andy Peng Xiang, Zhi‐liang Gao – 1 April 2017 – Mortality from hepatitis B virus (HBV)–related acute‐on‐chronic liver failure (ACLF) is high due to limited treatment options. Preclinical and clinical investigations have proved that treatment with mesenchymal stromal cells (MSCs) is beneficial for recovery from liver injury.

James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.

Chibuzo Iloabuchi, Amanda Stover, Pragya Rai, Yifan Zhang, Khalid M. Kamal – 31 March 2017

James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.

Eva Herrmann, Victor de Lédinghen, Christophe Cassinotto, Winnie C.‐W. Chu, Vivian Y.‐F. Leung, Giovanna Ferraioli, Carlo Filice, Laurent Castera, Valérie Vilgrain, Maxime Ronot, Jérôme Dumortier, Aymeric Guibal, Stanislas Pol, Jonel Trebicka, Christian Jansen, Christian Strassburg, Rongqin Zheng, Jian Zheng, Sven Francque, Thomas Vanwolleghem, Luisa Vonghia, Emanuel K.